DYP688
Phase 1/2Active 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Uveal Melanoma
Conditions
Metastatic Uveal Melanoma
Trial Timeline
Jul 4, 2022 → Oct 1, 2027
NCT ID
NCT05415072About DYP688
DYP688 is a phase 1/2 stage product being developed by Novartis for Metastatic Uveal Melanoma. The current trial status is active. This product is registered under clinical trial identifier NCT05415072. Target conditions include Metastatic Uveal Melanoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05415072 | Phase 1/2 | Active |
Competing Products
20 competing products in Metastatic Uveal Melanoma